Relationship between thrombospondin gene variations, von Willebrand factor levels and the risk of coronary heart disease in an older population

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 7, 2011, Pages 1415-1417

  van Loon, J E ^a   de Maat, M P M ^a   Hofman, Albert ^a   Witteman, J C M ^a   Leebeek, F W G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOSPONDIN; THROMBOSPONDIN 1; THROMBOSPONDIN 2; THROMBOSPONDIN 4; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; AGED; CARDIOVASCULAR RISK; CHROMOSOME 15; CHROMOSOME 5; CHROMOSOME 6; COHORT ANALYSIS; CORONARY ARTERY BYPASS GRAFT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; LETTER; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVASCULARIZATION; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; CORONARY DISEASE; FEMALE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; THROMBOSPONDINS; VON WILLEBRAND FACTOR;

EID: 79959817490     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04314.x     Document Type: Letter

References (19)

1. Martinelli I. von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Semin Hematol 2005; 42: 49-55.
2. Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997; 34: 255-65.
3. Smith NL, Chen MH, Dehghan A, Strachan DP, Basu S, Soranzo N, Hayward C, Rudan I, Sabater-Lleal M, Bis JC, de Maat MP, Rumley A, Kong X, Yang Q, Williams FM, Vitart V, Campbell H, Malarstig A, Wiggins KL, van Duijn CM et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: the CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 2010; 121: 1382-92.
4. van Loon JE, Leebeek FW, Deckers JW, Dippel DW, Poldermans D, Strachan DP, Tang W, O'Donnell CJ, Smith NL, de Maat MP. Effect of genetic variations in syntaxin-binding protein-5 and syntaxin-2 on von Willebrand factor concentration and cardiovascular risk. Circ Cardiovasc Genet 2010; 3: 507-12.
5. van Schie MC, van Loon JE, De Maat MPM, Leebeek FWG. Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease. A review. J Thromb Haemost 2011; 9: 899-908.
6. Bongers TN, de Bruijne EL, Dippel DW, de Jong AJ, Deckers JW, Poldermans D, de Maat MP, Leebeek FW. Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis 2009; 207: 250-4.
7. Bonnefoy A, Hoylaerts MF. Thrombospondin-1 in von Willebrand factor function. Curr Drug Targets 2008; 9: 822-32.
8. Bonnefoy A, Daenens K, Feys HB, De Vos R, Vandervoort P, Vermylen J, Lawler J, Hoylaerts MF. Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13. Blood 2006; 107: 955-64.
9. Stenina OI, Topol EJ, Plow EF. Thrombospondins, their polymorphisms, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007; 27: 1886-94.
10. Topol EJ, McCarthy J, Gabriel S, Moliterno DJ, Rogers WJ, Newby LK, Freedman M, Metivier J, Cannata R, O'Donnell CJ, Kottke-Marchant K, Murugesan G, Plow EF, Stenina O, Daley GQ. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 2001; 104: 2641-4.
11. Boekholdt SM, Trip MD, Peters RJ, Engelen M, Boer JM, Feskens EJ, Zwinderman AH, Kastelein JJ, Reitsma PH. Thrombospondin-2 polymorphism is associated with a reduced risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol 2002; 22: e24-7.
12. Koch W, Hoppmann P, de Waha A, Schomig A, Kastrati A. Polymorphisms in thrombospondin genes and myocardial infarction: a case-control study and a meta-analysis of available evidence. Hum Mol Genet 2008; 17: 1120-6.
13. Morgan TM, Krumholz HM, Lifton RP, Spertus JA. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 2007; 297: 1551-61.
14. Zwicker JI, Peyvandi F, Palla R, Lombardi R, Canciani MT, Cairo A, Ardissino D, Bernardinelli L, Bauer KA, Lawler J, Mannucci P. The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. Blood 2006; 108: 1280-3.
15. Hofman A, Breteler MM, van Duijn CM, Janssen HL, Krestin GP, Kuipers EJ, Stricker BH, Tiemeier H, Uitterlinden AG, Vingerling JR, Witteman JC. The Rotterdam Study: 2010 objectives and design update. Eur J Epidemiol 2009; 24: 553-72.
16. de Bruyne MC, Mosterd A, Hoes AW, Kors JA, Kruijssen DA, van Bemmel JH, Hofman A, Grobbee DE. Prevalence, determinants, and misclassification of myocardial infarction in the elderly. Epidemiology 1997; 8: 495-500.
17. Storey J. A direct approach to false discovery rates. J R Stat Soc 2002; 64: 479-98.
18. Wessel J, Topol EJ, Ji M, Meyer J, McCarthy JJ. Replication of the association between the thrombospondin-4 A387P polymorphism and myocardial infarction. Am Heart J 2004; 147: 905-9.
19. Cui J, Randell E, Renouf J, Sun G, Green R, Han FY, Xie YG. Thrombospondin-4 1186G>C (A387P) is a sex-dependent risk factor for myocardial infarction: a large replication study with increased sample size from the same population. Am Heart J 2006; 152: 543 e1-5.